Compare Abeona Therapeutics Inc (ABEO) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Micron Technology, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Micron Technology, Inc. trades at $897 (market cap $980.90B). The key difference: Micron Technology, Inc. is far larger — about 2328.9× Abeona Therapeutics Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MU | |
|---|---|---|
Market Cap | $421.19M | $980.90B |
Sector | Health | Technology |
52-Week High | $7.45 | $1.21K |
52-Week Low | $4.17 | $115.79 |
Enterprise Value | $276.10M | $961.25B |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Micron Technology (MU) trades at $861.00, down 1.89% amid recent volatility despite strong fundamental performance. The stock shows neutral technical signals with key support at $845 and resistance at $886. Fundamentally, MU demonstrates exceptional profitability with 72.57% gross margins and 55.91% net income margins, supported by three consecutive quarterly earnings beats. Revenue growth accelerated to $37.38 billion in 2025 from $25.1 billion in 2024, with projected 2026 revenue of $90.3 billion indicating robust AI-driven demand.
The outlook remains positive with 81% analyst buy ratings and $1,540 consensus price target representing 79% upside. However, cyclical memory market risks and competitive threats from new entrants like SpaceX's Terrafab facility pose challenges. The stock's current valuation at 19.63 P/E appears reasonable given projected earnings growth, making MU attractive for investors comfortable with semiconductor sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
